IceCure Medical grants VP HR 73,890 RSUs

IceCure Medical Ltd. reported that executive Dotan Merav Nir, VP Human Resources, received a compensation-related equity award.

Rhea-AI Filing Summary

IceCure Medical Ltd. reported that executive Dotan Merav Nir, VP Human Resources, received a compensation-related equity award. On August 14, 2026 he was granted 73,890 restricted share units (RSUs) with no cash exercise price. Following this grant, his reported holdings total 76,168 ordinary shares and RSUs, consisting of the new award plus previously granted RSUs and 17 ordinary shares. The new 73,890-RSU grant vests 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter.

Insider Trade Summary

Grant/Award: 73,890 shares

Grant/Award 1 txn

Insider Dotan Merav Nir

Role VP, Human Resources

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	73,890	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 76,168 shares (Direct)

Footnotes (1)

1. F1. Represents (i) 73,890 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 17 ordinary shares, (iii) 758 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,080 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 440 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

Key Figures

New RSU grant: 73,890 RSUs Total holdings after transaction: 76,168 shares/RSUs Transaction price per share: $0.0000 +5 more

8 metrics

New RSU grant 73,890 RSUs Restricted share units granted to Dotan Merav Nir on August 14, 2026

Total holdings after transaction 76,168 shares/RSUs Ordinary shares and RSUs held by Dotan Merav Nir following the August 14, 2026 grant

Transaction price per share $0.0000 Reported per-share transaction price for the RSU grant

Initial vesting tranche 25% Portion of each RSU grant that vests on the first specified vesting date

Quarterly vesting installments 6.25% per quarter Rate at which the remaining 75% of each RSU grant vests, in equal quarterly installments

Prior RSU grant (July 2, 2024) 758 RSUs RSUs granted on July 2, 2024 to Dotan Merav Nir

Prior RSU grant (November 5, 2025) 1,080 RSUs RSUs granted on November 5, 2025 to Dotan Merav Nir

Prior RSU grant (March 16, 2026) 440 RSUs RSUs granted on March 16, 2026 to Dotan Merav Nir

Key Terms

restricted share units, vest, reverse share split

3 terms

restricted share units financial

"Represents (i) 73,890 restricted share units ("RSUs") granted on August 14, 2026"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

vest financial

"25% of which vest on August 11, 2027, and the remaining 75% vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

reverse share split financial

"have been adjusted to reflect the Issuer's 1-for-30 reverse share split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did IceCure Medical (ICCM) grant to Dotan Merav Nir on August 14, 2026?

IceCure Medical granted 73,890 restricted share units (RSUs) to VP Human Resources Dotan Merav Nir on August 14, 2026 as a compensation-related equity award, reported at a $0.0000 per-share transaction price.

What are Dotan Merav Nir’s total reported holdings in IceCure Medical (ICCM) after this Form 4 transaction?

After the reported award, Dotan Merav Nir holds 76,168 IceCure Medical ordinary shares and RSUs in total, including 73,890 newly granted RSUs, 17 ordinary shares, and previously granted RSUs that remain outstanding as of August 13, 2026.

How do the 73,890 new RSUs for IceCure Medical (ICCM) executive Dotan Merav Nir vest?

The 73,890 RSUs granted on August 14, 2026 vest 25% on August 11, 2027. The remaining 75% then vest in twelve equal quarterly installments of 6.25% each, creating a multi-year vesting schedule tied to continued service.

What earlier RSU grants to Dotan Merav Nir are referenced in this IceCure Medical (ICCM) Form 4?

The filing references RSU grants of 758 RSUs on July 2, 2024, 1,080 RSUs on November 5, 2025, and 440 RSUs on March 16, 2026. Each grant vests 25% on a stated first vesting date, with the remaining 75% in equal quarterly installments.

Which RSUs for IceCure Medical (ICCM) executive Dotan Merav Nir are unvested as of August 13, 2026?

Except for the 25% tranche of the 758 RSUs granted on July 2, 2024 that vested on July 29, 2026, all RSUs described in the filing remain unvested as of August 13, 2026, including the new 73,890-unit award.

How did IceCure Medical’s 1-for-30 reverse share split affect Dotan Merav Nir’s reported holdings?

The filing states that holdings from items (ii) through (v)—including 17 ordinary shares and earlier RSU grants—have been adjusted to reflect the issuer's 1-for-30 reverse share split, so the reported share and RSU counts already incorporate that adjustment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 08:16 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dotan Merav Nir

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Human Resources

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		A		73,890	A	$0	76,168(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) 73,890 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 17 ordinary shares, (iii) 758 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,080 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 440 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

	/s/ Merav Nir Dotan	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)